The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer

Cell Reports

Volumn 17, Issue 5, 2016, Pages 1302-1317

  Zhou, Wenhui ^a,b   Ni, Thomas K ^a,b   Wronski, Ania ^a,b   Glass, Benjamin ^c   Skibinski, Adam ^a,b   Beck, Andrew ^c   Kuperwasser, Charlotte ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

acetylation; basal like breast cancer; deacetylase; protein stability; SIRT2; sirtinol; Slug; triple negative breast cancer

Indexed keywords

SIRTUIN 2; TRANSCRIPTION FACTOR SLUG; LYSINE; PROTEIN BINDING; TRANSCRIPTION FACTOR SNAIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; TUMOR GROWTH; AMINO ACID SEQUENCE; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; ENZYME SPECIFICITY; GENE SILENCING; HEK293 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROTEOMICS; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE SILENCING; HEK293 CELLS; HUMANS; LYSINE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; PROTEIN BINDING; PROTEIN STABILITY; PROTEOMICS; SIRTUIN 2; SNAIL FAMILY TRANSCRIPTION FACTORS; SUBSTRATE SPECIFICITY;

EID: 84994766846     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.10.006     Document Type: Article

References (68)

1. Anders, C.K., Carey, L.A., Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 9:Suppl 2 (2009), S73–S81.
2. Black, J.C., Mosley, A., Kitada, T., Washburn, M., Carey, M., The SIRT2 deacetylase regulates autoacetylation of p300. Mol. Cell 32 (2008), 449–455.
3. Bolós, V., Peinado, H., Pérez-Moreno, M.A., Fraga, M.F., Esteller, M., Cano, A., The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 116 (2003), 499–511.
4. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
5. Chang, T.-H.H., Tsai, M.-F.F., Su, K.-Y.Y., Wu, S.-G.G., Huang, C.-P.P., Yu, S.-L.L., Yu, Y.-L.L., Lan, C.-C.C., Yang, C.-H.H., Lin, S.-B.B., et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am. J. Respir. Crit. Care Med. 183 (2011), 1071–1079.
6. Chen, J., Chan, A.W., To, K.-F.F., Chen, W., Zhang, Z., Ren, J., Song, C., Cheung, Y.-S.S., Lai, P.B., Cheng, S.-H.H., et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. Hepatology 57 (2013), 2287–2298.
7. Cobaleda, C., Pérez-Caro, M., Vicente-Dueñas, C., Sánchez-García, I., Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu. Rev. Genet. 41 (2007), 41–61.
8. Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., Forbes, J.F., ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11 (2010), 1135–1141.
9. Dan, L., Klimenkova, O., Klimiankou, M., Klusman, J.-H.H., van den Heuvel-Eibrink, M.M., Reinhardt, D., Welte, K., Skokowa, J., The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 97 (2012), 551–559.
10. DiMeo, T.A., Anderson, K., Phadke, P., Fan, C., Perou, C.M., Naber, S., Kuperwasser, C., A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69 (2009), 5364–5373.
11. Fan, C., Oh, D.S., Wessels, L., Weigelt, B., Nuyten, D.S., Nobel, A.B., van't Veer, L.J., Perou, C.M., Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 (2006), 560–569.
12. Fillmore, C.M., Kuperwasser, C., Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 10, 2008, R25.
13. Foulkes, W.D., Smith, I.E., Reis-Filho, J.S., Triple-negative breast cancer. N. Engl. J. Med. 363 (2010), 1938–1948.
14. Fujita, Y., Fujiwara, K., Zenitani, S., Yamashita, T., Acetylation of NDPK-D regulates its subcellular localization and cell survival. PLoS One, 10, 2015, e0139616.
15. Grbesa, I., Pajares, M.J.J., Martínez-Terroba, E., Agorreta, J., Mikecin, A.-M.M., Larráyoz, M., Idoate, M.A., Gall-Troselj, K., Pio, R., Montuenga, L.M., Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One, 10, 2015, e0124670.
16. Guarente, L., Franklin H. Epstein lecture: sirtuins, aging, and medicine. N Engl J Med. 364 (2011), 2235–2244.
17. Guo, W., Keckesova, Z., Donaher, J.L., Shibue, T., Tischler, V., Reinhardt, F., Itzkovitz, S., Noske, A., Zürrer-Härdi, U., Bell, G., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148 (2012), 1015–1028.
18. Gusterson, B., Do “basal-like” breast cancers really exist?. Nat. Rev. Cancer 9 (2009), 128–134.
19. Hajra, K., Chen, D., Fearon, E., The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62 (2002), 1613–1618.
20. Harris, J.R., Lippman, M.E., Osborne, C.K., Morrow, M., Diseases of the Breast. 2012, Lippincott Williams & Wilkins.
21. Heltweg, B., Gatbonton, T., Schuler, A.D., Posakony, J., Li, H., Goehle, S., Kollipara, R., Depinho, R.A., Gu, Y., Simon, J.A., Bedalov, A., Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66 (2006), 4368–4377.
22. Hoffmann, G., Breitenbücher, F., Schuler, M., Ehrenhofer-Murray, A.E., A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J. Biol. Chem. 289 (2014), 5208–5216.
23. Hsu, D., Wang, H.-J., Tai, S.-K., Chou, C.-H., Hsieh, C.-H., Chiu, P.-H., Chen, N.-J., Yang, M.-H., Acetylation of snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. Cancer Cell 26 (2014), 534–548.
24. Ignatiadis, M., Singhal, S.K., Desmedt, C., Haibe-Kains, B., Criscitiello, C., Andre, F., Loi, S., Piccart, M., Michiels, S., Sotiriou, C., Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30 (2012), 1996–2004.
25. Jiang, W., Wang, S., Xiao, M., Lin, Y., Zhou, L., Lei, Q., Xiong, Y., Guan, K.-L.L., Zhao, S., Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol. Cell 43 (2011), 33–44.
26. Jing, H., Hu, J., He, B., Negrón Abril, Y.L., Stupinski, J., Weiser, K., Carbonaro, M., Chiang, Y.-L.L., Southard, T., Giannakakou, P., et al. A SIRT2-selective inhibitor promotes c-myc oncoprotein degradation and exhibits broad anticancer activity. Cancer Cell 29 (2016), 297–310.
27. Kao, S.-H.H., Wang, W.-L.L., Chen, C.-Y.Y., Chang, Y.-L.L., Wu, Y.-Y.Y., Wang, Y.-T.T., Wang, S.-P.P., Nesvizhskii, A.I., Chen, Y.-J.J., Hong, T.-M.M., Yang, P.C., GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 33 (2014), 3172–3182.
28. Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M.C., Voduc, D., Speers, C.H., Nielsen, T.O., Gelmon, K., Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28 (2010), 3271–3277.
29. Kim, S., Yao, J., Suyama, K., Qian, X., Qian, B.Z., Bandyopadhyay, S., Loudig, O., De Leon-Rodriguez, C., Zhou, Z.N., Segall, J., et al. Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis. Cancer Res. 74 (2014), 3695–3706.
30. Kurrey, N.K., Jalgaonkar, S.P., Joglekar, A.V., Ghanate, A.D., Chaskar, P.D., Doiphode, R.Y., Bapat, S.A., Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27 (2009), 2059–2068.
31. Lander, R., Nordin, K., LaBonne, C., The F-box protein Ppa is a common regulator of core EMT factors Twist, Snail, Slug, and Sip1. J. Cell Biol. 194 (2011), 17–25.
32. Liu, P.Y., Xu, N., Malyukova, A., Scarlett, C.J., Sun, Y.T., Zhang, X.D., Ling, D., Su, S.-P.P., Nelson, C., Chang, D.K., et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20 (2013), 503–514.
33. Liu, T., Zhang, X., Shang, M., Zhang, Y., Xia, B., Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J. Surg. Oncol. 107 (2013), 188–194.
34. Martin, T.A., Goyal, A., Watkins, G., Jiang, W.G., Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 12 (2005), 488–496.
35. McCarthy, A.R., Sachweh, M.C., Higgins, M., Campbell, J., Drummond, C.J., van Leeuwen, I.M., Pirrie, L., Ladds, M.J., Westwood, N.J., Laín, S., Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. Mol. Cancer Ther. 12 (2013), 352–360.
36. Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K.S., Viale, G., Loi, S., Bradbury, I., Bliss, J.M., Azim, H.A. Jr., Ellis, P., et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30 (2012), 1879–1887.
37. Nassour, M., Idoux-Gillet, Y., Selmi, A., Côme, C., Faraldo, M.-L.M.L., Deugnier, M.-A.A., Savagner, P., Slug controls stem/progenitor cell growth dynamics during mammary gland morphogenesis. PLoS One, 7, 2012, e53498.
38. North, B.J., Verdin, E., Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J. Biol. Chem. 282 (2007), 19546–19555.
39. +-dependent tubulin deacetylase. Mol. Cell 11 (2003), 437–444.
40. Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000), 747–752.
41. Phillips, S., Kuperwasser, C., SLUG: Critical regulator of epithelial cell identity in breast development and cancer. Cell Adhes. Migr. 8 (2014), 578–587.
42. Phillips, S., Prat, A., Sedic, M., Proia, T., Wronski, A., Mazumdar, S., Skibinski, A., Shirley, S.H., Perou, C.M., Gill, G., et al. Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Reports 2 (2014), 633–647.
43. Polyak, K., Weinberg, R.A., Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9 (2009), 265–273.
44. Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., Pilotti, S., Pierotti, M.A., Daidone, M.G., Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65 (2005), 5506–5511.
45. Prasad, C.P., Rath, G., Mathur, S., Bhatnagar, D., Parshad, R., Ralhan, R., Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer, 9, 2009, 325.
46. Proia, T.A., Keller, P.J., Gupta, P.B., Klebba, I., Jones, A.D., Sedic, M., Gilmore, H., Tung, N., Naber, S.P., Schnitt, S., et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8 (2011), 149–163.
47. Rakha, E.A., Reis-Filho, J.S., Ellis, I.O., Basal-like breast cancer: a critical review. J. Clin. Oncol. 26 (2008), 2568–2581.
48. Regan, M.M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J.F., Smith, I., Láng, I., Wardley, A., et al. BIG 1-98 Collaborative Group, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 12 (2011), 1101–1108.
49. Rotili, D., Tarantino, D., Nebbioso, A., Paolini, C., Huidobro, C., Lara, E., Mellini, P., Lenoci, A., Pezzi, R., Botta, G., et al. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J. Med. Chem. 55 (2012), 10937–10947.
50. Samanta, S., Sun, H., Goel, H.L., Pursell, B., Chang, C., Khan, A., Greiner, D.L., Cao, S., Lim, E., Shultz, L.D., Mercurio, A.M., IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG. Oncogene 35 (2016), 1111–1121.
51. Singh, S., Kumar, P.U., Thakur, S., Kiran, S., Sen, B., Sharma, S., Rao, V.V., Poongothai, A.R., Ramakrishna, G., Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells. Tumour Biol. 36 (2015), 6159–6171.
52. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001), 783–792.
53. Song, E.H., Oh, W., Ulu, A., Carr, H.S., Zuo, Y., Frost, J.A., Acetylation of the RhoA GEF Net1A controls its subcellular localization and activity. J. Cell Sci. 128 (2015), 913–922.
54. Storci, G., Sansone, P., Trere, D., Tavolari, S., Taffurelli, M., Ceccarelli, C., Guarnieri, T., Paterini, P., Pariali, M., Montanaro, L., et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J. Pathol. 214 (2008), 25–37.
55. Taube, J.H., Herschkowitz, J.I., Komurov, K., Zhou, A.Y., Gupta, S., Yang, J., Hartwell, K., Onder, T.T., Gupta, P.B., Evans, K.W., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 107 (2010), 15449–15454.
56. Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2 (2002), 442–454.
57. van de Vijver, M.J., He, Y.D., van't Veer, L.J., Dai, H., Hart, A.A., Voskuil, D.W., Schreiber, G.J., Peterse, J.L., Roberts, C., Marton, M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002), 1999–2009.
58. van't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002), 530–536.
59. Vernon, A.E., LaBonne, C., Slug stability is dynamically regulated during neural crest development by the F-box protein Ppa. Development 133 (2006), 3359–3370.
60. Viñas-Castells, R., Beltran, M., Valls, G., Gómez, I., García, J.M., Montserrat-Sentís, B., Baulida, J., Bonilla, F., de Herreros, A.G., Díaz, V.M., The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation. J. Biol. Chem. 285 (2010), 3794–3805.
61. Wang, F., Chan, C.-H.H., Chen, K., Guan, X., Lin, H.-K.K., Tong, Q., Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 31 (2012), 1546–1557.
62. Wang, S.-P.P., Wang, W.-L.L., Chang, Y.-L.L., Wu, C.-T.T., Chao, Y.-C.C., Kao, S.-H.H., Yuan, A., Lin, C.-W.W., Yang, S.-C.C., Chan, W.-K.K., et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 11 (2009), 694–704.
63. Wu, W.-S.S., Heinrichs, S., Xu, D., Garrison, S.P., Zambetti, G.P., Adams, J.M., Look, A.T., Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123 (2005), 641–653.
64. Wu, Z.-Q.Q., Li, X.-Y.Y., Hu, C.Y., Ford, M., Kleer, C.G., Weiss, S.J., Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc. Natl. Acad. Sci. USA 109 (2012), 16654–16659.
65. Yang, J., Weinberg, R.A., Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14 (2008), 818–829.
66. Zhang, H., Head, P.E., Daddacha, W., Park, S.-H.H., Li, X., Pan, Y., Madden, M.Z., Duong, D.M., Xie, M., Yu, B., et al. ATRIP deacetylation by SIRT2 drives ATR checkpoint activation by promoting binding to RPA-ssDNA. Cell Rep. 14 (2016), 1435–1447.
67. Zhang, Y., Au, Q., Zhang, M., Barber, J.R., Ng, S.C., Zhang, B., Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem. Biophys. Res. Commun. 386 (2009), 729–733.
68. Zhao, D., Mo, Y., Li, M.-T.T., Zou, S.-W.W., Cheng, Z.-L.L., Sun, Y.-P.P., Xiong, Y., Guan, K.-L.L., Lei, Q.-Y.Y., NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J. Clin. Invest. 124 (2014), 5453–5465.